Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Neoplasms 21Melanoma 20Carcinoma, Non-Small-Cell Lung 12Neoplasm Metastasis 9Pancreatic Neoplasms 8Colorectal Neoplasms 8Rectal Neoplasms 4Triple Negative Breast Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Colonic Neoplasms 3Thyroid Neoplasms 2Meningioma 2Leukemia, Myeloid, Acute 2Glioma 2Breast Neoplasms 2Brain Neoplasms 2Advanced Solid Tumors 2Adenocarcinoma of Lung 2Thyroid Carcinoma, Anaplastic 1Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors, KRAS Mutation; SOS1 1Solid Tumors 1Solid Tumor Cancer 1Solid Tumor 1Sarcoma 1Rhabdoid Tumor 1Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer 1Recurrence 1

Interventions

pembrolizumab 24Paclitaxel 20Carboplatin 19Taxes 7temsirolimus 6Trastuzumab 6Topotecan 5Radiotherapy 5Cisplatin 5atezolizumab 4Specimen Handling 4Nivolumab 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Gemcitabine 4Docetaxel 4Biopsy 4Bevacizumab 4olaparib 3lenvatinib 3dostarlimab 3Sirolimus 3Pemetrexed 3Irinotecan 3Interleukin-12 Subunit p35 3Fulvestrant 3Cetuximab 3Albumin-Bound Paclitaxel 3spartalizumab 2gedatolisib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Endometrial Neoplasms × trametinib × Clear all
NCT01138085 2017-11-13

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

GlaxoSmithKline

Phase 1 Completed
240 enrolled
BreastGynecologic

Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡